Your browser is no longer supported. Please, upgrade your browser.
NBRV Nabriva Therapeutics plc daily Stock Chart
NBRV [NASD]
Nabriva Therapeutics plc
Index- P/E- EPS (ttm)-1.53 Insider Own2.00% Shs Outstand94.55M Perf Week4.00%
Market Cap147.50M Forward P/E- EPS next Y-0.92 Insider Trans3.56% Shs Float93.37M Perf Month0.00%
Income-90.50M PEG- EPS next Q-0.33 Inst Own43.10% Short Float4.98% Perf Quarter-13.81%
Sales9.90M P/S14.90 EPS this Y9.30% Inst Trans13.09% Short Ratio3.49 Perf Half Y-23.90%
Book/sh0.52 P/B3.00 EPS next Y20.00% ROA-93.30% Target Price7.00 Perf Year-23.15%
Cash/sh0.83 P/C1.88 EPS next 5Y- ROE-171.40% 52W Range1.16 - 3.27 Perf YTD18.18%
Dividend- P/FCF- EPS past 5Y-19.10% ROI-124.00% 52W High-52.29% Beta2.36
Dividend %- Quick Ratio5.80 Sales past 5Y- Gross Margin99.80% 52W Low34.48% ATR0.10
Employees110 Current Ratio5.80 Sales Q/Q1401.10% Oper. Margin- RSI (14)62.57 Volatility6.26% 7.14%
OptionableYes Debt/Eq0.87 EPS Q/Q73.80% Profit Margin- Rel Volume0.40 Prev Close1.56
ShortableYes LT Debt/Eq0.87 EarningsMar 10 AMC Payout- Avg Volume1.33M Price1.56
Recom1.90 SMA209.40% SMA507.05% SMA200-21.28% Volume538,081 Change0.00%
May-02-19Upgrade Gabelli & Co Sell → Hold
May-02-19Reiterated H.C. Wainwright Buy $9 → $7
Sep-07-18Resumed Morgan Stanley Overweight
Mar-21-18Initiated BofA/Merrill Buy $10
Jan-17-18Initiated Morgan Stanley Overweight
Nov-01-17Reiterated H.C. Wainwright Buy $18 → $20
Aug-25-17Initiated SunTrust Buy $20
Feb-01-17Reiterated Wedbush Outperform $13
Oct-27-16Resumed Leerink Partners Outperform $14
Sep-08-16Initiated H.C. Wainwright Buy $16
Jan-27-16Initiated Gabelli & Co Buy $14
Nov-12-15Reiterated RBC Capital Mkts Outperform $21 → $22
Oct-13-15Initiated Wedbush Outperform
Oct-13-15Initiated RBC Capital Mkts Outperform $21
Oct-13-15Initiated Leerink Partners Outperform $19
Oct-12-15Initiated Needham Buy $15
Feb-05-20 04:01PM  Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jan-22-20 08:24AM  Will Nabriva Therapeutics Continue to Surge Higher? Zacks
Jan-09-20 08:39AM  The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results Benzinga
Jan-08-20 04:01PM  Nabriva Therapeutics Receives FDA Acknowledgement of New Drug Application Resubmission for Intravenous CONTEPO (fosfomycin) for Injection GlobeNewswire
Dec-20-19 03:06PM  Nabriva takes another shot at getting infection drug approved; raising $20M American City Business Journals -25.58%
08:37AM  Nabriva Therapeutics Announces $20 Million Registered Direct Offering GlobeNewswire
06:44AM  Nabriva's stock soars after resubmitting NDA for UTI treatment MarketWatch
06:00AM  Nabriva Therapeutics Resubmits New Drug Application for Intravenous CONTEPO (fosfomycin) for Injection GlobeNewswire
Dec-19-19 09:38PM  Smart Money Is Buying Nabriva Therapeutics plc (NBRV) Insider Monkey
Dec-10-19 10:31AM  Investors Who Bought Nabriva Therapeutics (NASDAQ:NBRV) Shares A Year Ago Are Now Down 11% Simply Wall St.
Dec-02-19 04:01PM  Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-23-19 06:55PM  Bulls And Bears Of The Week: Nio, Target, Apple and More Benzinga
Nov-21-19 04:01PM  Nabriva Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-20-19 07:49PM  Biotech Stock On The Radar: Nabriva And Its Novel Antibiotic Portfolio Benzinga
Nov-18-19 07:00AM  Nabriva Therapeutics Commends the CDC on the 2019 Antibiotic Resistance Threats Report, Highlighting the Need for New Antibiotics Aligned with Antibiotic Stewardship GlobeNewswire
Nov-12-19 04:01PM  Nabriva Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights GlobeNewswire
Nov-01-19 04:01PM  Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Oct-31-19 07:00AM  Nabriva Therapeutics to Report Third-Quarter 2019 Financial Results on November 12, 2019 GlobeNewswire
Oct-15-19 07:00AM  Nabriva to Present Data at the CHEST Annual Meeting Demonstrating the Safety and Efficacy of Newly FDA-Approved XENLETA (lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) GlobeNewswire
Oct-11-19 06:32PM  3 Strong Buy Biotech Stocks That Could Triple in 2020 TipRanks
Oct-01-19 04:01PM  Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
10:07AM  Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019 PR Newswire
Sep-27-19 12:15PM  Lefamulin Evaluation Against Pneumonia 2 (LEAP 2) Study Results Published in the Journal of the American Medical Association GlobeNewswire
Sep-26-19 04:01PM  Nabriva to Present Data from XENLETA (lefamulin) and CONTEPO (fosfomycin) Development Programs at IDWeek 2019 GlobeNewswire
Sep-18-19 07:00AM  Nabriva Therapeutics to Present at the 2019 Cantor Global Healthcare Conference GlobeNewswire
Sep-11-19 09:32AM  Is Nabriva Therapeutics (NASDAQ:NBRV) Using Too Much Debt? Simply Wall St.
Sep-09-19 07:00AM  Nabrivas XENLETA (lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) Now Available in the U.S. GlobeNewswire +7.28%
Sep-06-19 04:01PM  Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
07:00AM  Nabriva Therapeutics Earns $5 Million Milestone Payment under its License Agreement with Sinovant Sciences GlobeNewswire
Aug-29-19 09:15AM  Nabriva Therapeutics Plc (NBRV) CEO Theodore R Schroeder Bought $89,500 of Shares GuruFocus.com
Aug-28-19 07:00AM  Nabriva Therapeutics to Present at the 17th Annual Morgan Stanley Global Healthcare Conference GlobeNewswire +16.67%
Aug-21-19 12:15PM  A Look At Benzinga Pro's Most-Searched Tickers For August 21, 2019 Benzinga -8.07%
11:00AM  Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More Zacks
Aug-20-19 04:47PM  Nabriva (NBRV) Gains FDA Approval for Pneumonia Drug Xenleta Zacks
02:40PM  FDA Nods Fuel Unusual Options Volume on NBRV, MRNA Schaeffer's Investment Research
12:42PM  Nabriva Analysts Bullish After FDA OKs Antibiotic; BofA Sees $200M Sales Potential Benzinga
08:36AM  Nabriva Shares Rip Higher Following FDA Nod For Novel Antibiotic Benzinga
08:33AM  Nabriva Therapeutics' stock soars in heavy volume after FDA approves NDA for CABP treatment MarketWatch
07:33AM  The Daily Biotech Pulse: FDA Likes Nabriva's Antibiotic, Snubs Sarepta's DMD Drug; Moderna Gets Fast Track Designation For Zika Vaccine Benzinga
Aug-19-19 08:33PM  FDA approves King of Prussia company's pneumonia drug American City Business Journals
05:55PM  Nabriva (NBRV) Aims to Resubmit Contepo NDA in Q4 Zacks
03:45PM  UPDATE 2-Nabriva prices two pneumonia antibiotic versions at over $200 per day Reuters
03:41PM  Nabriva Therapeutics Receives U.S. FDA Approval of Xenleta (lefamulin) to Treat Community-Acquired Bacteria Pneumonia (CABP) GlobeNewswire
03:10PM  FDA approves Nabriva's antibiotic for pneumonia Reuters
Aug-17-19 01:46PM  The Week Ahead In Biotech: FDA Goes Into Overdrive In A Quiet Week Benzinga
Aug-16-19 11:17AM  Nabriva Shares Volatile As Biopharma Updates FDA Filing Timeline Benzinga +5.56%
07:33AM  The Daily Biotech Pulse: Roche Snags Double Nod For Personalized Cancer Drug, Bellicum Offering, Nabriva Braces For Contepo Resubmission Benzinga
07:00AM  Nabriva Therapeutics Provides Update on the Planned Resubmission of the New Drug Application for Intravenous CONTEPO (fosfomycin) for Injection GlobeNewswire
Aug-14-19 01:02PM  Is the Options Market Predicting a Spike in Nabriva (NBRV) Stock? Zacks
Aug-08-19 07:00AM  Nabriva Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights GlobeNewswire +5.56%
Aug-06-19 07:00AM  Nabriva Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference GlobeNewswire
Jul-18-19 02:36PM  Are Insiders Buying Nabriva Therapeutics plc (NASDAQ:NBRV) Stock? Simply Wall St.
Jul-17-19 04:02PM  Melinta (MLNT) Announces Preliminary Product Sales for Q2 Zacks
Jul-08-19 01:35PM  SHAREHOLDER DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nabriva Therapeutics plc and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
11:37AM  FINAL DEADLINE: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Nabriva Therapeutics plc Investors of Important Deadline Today in the Securities Class Action NBRV GlobeNewswire
10:23AM  FINAL DEADLINE ALERT - (NBRV) Nabriva Therapeutics PLC Bronstein, Gewirtz & Grossman, LLC Reminds Investors with Losses Exceeding $50K of Class Action and Lead Plaintiff Deadline: July 8, 2019 ACCESSWIRE
10:00AM  MONDAY DEADLINE REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Nabriva Therapeutics plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
Jul-05-19 07:30PM  FINAL DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nabriva Therapeutics plc and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
03:00PM  DEADLINE ALERT - (NBRV) Nabriva Therapeutics PLC Bronstein, Gewirtz & Grossman, LLC Reminds Investors with Losses Exceeding $50K of Class Action and Lead Plaintiff Deadline: July 8, 2019 GlobeNewswire
10:47AM  MONDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nabriva Therapeutics plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
10:28AM  DEADLINE ALERT - (NBRV) Nabriva Therapeutics PLC Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders with Losses Exceeding $50K of Class Action and Lead Plaintiff Deadline: July 8, 2019 ACCESSWIRE
10:00AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nabriva Therapeutics plc of Class Action Lawsuit and Upcoming Deadline NBRV GlobeNewswire
Jul-03-19 05:25PM  5-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nabriva Therapeutics plc and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
11:25AM  TOP RANKED ROSEN LAW FIRM: Announces Securities Class Action Lawsuit Against Nabriva Therapeutics plc; IMPORTANT JULY 8 DEADLINE - NBRV ACCESSWIRE
09:50AM  DEADLINE ALERT - (NBRV) Nabriva Therapeutics PLC Bronstein, Gewirtz & Grossman, LLC Reminds Investors with Losses Exceeding $50K of Class Action and Lead Plaintiff Deadline: July 8, 2019 ACCESSWIRE
08:30AM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Nabriva Therapeutics, Equity Bancshares, Revlon and AAC Holdings and Encourages Investors to Contact the Firm GlobeNewswire
Jul-02-19 01:39PM  JULY 8 DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nabriva Therapeutics plc and Encourages Investors with Losses in Excess of $50,000 to Contact the Firm ACCESSWIRE
11:01AM  NBRV: Zhang Investor Law Reminds Investors of July 8 Deadline in Securities Class Action Lawsuit Nabriva Therapeutics plc NBRV GlobeNewswire
Jul-01-19 03:27PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nabriva Therapeutics plc of Class Action Lawsuit and Upcoming Deadline - NBRV ACCESSWIRE
10:30AM  DEADLINE ALERT - Nabriva Therapeutics PLC (NBRV) Bronstein, Gewirtz & Grossman, LLC Reminds Investors with Losses Exceeding $50K of Class Action and Lead Plaintiff Deadline: July 8, 2019 ACCESSWIRE
10:06AM  7-DAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nabriva Therapeutics plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
09:13AM  X-Biotix Therapeutics Joins Antimicrobials Working Group PR Newswire
Jun-30-19 05:51PM  FINAL DEADLINE APPROACHING: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nabriva Therapeutics plc and Encourages Investors with Losses in Excess of $50,000 to Contact the Firm ACCESSWIRE
04:00PM  ROSEN, A TOP RANKED LAW FIRM, Reminds Nabriva Therapeutics plc Investors of Important July 8th Deadline in the Securities Class Action NBRV GlobeNewswire
Jun-28-19 05:33PM  Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nabriva Therapeutics plc GlobeNewswire +9.46%
03:00PM  KSHB, NBRV & EQBK- Class Action Upcoming Deadline - Bronstein, Gewirtz & Grossman, LLC GlobeNewswire
10:18AM  Upcoming Class Action Deadline KSHB, NBRV & EQBK - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Jun-27-19 09:30PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against KushCo Holdings, Nabriva Therapeutics, Equity Bancshares, and Revlon and Encourages Investors to Contact the Firm GlobeNewswire
12:32PM  UPCOMING DEADLINE REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Nabriva Therapeutics plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
Jun-26-19 05:15PM  EARLY JULY DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nabriva Therapeutics plc and Encourages Investors with Losses in Excess of $50,000 to Contact the Firm ACCESSWIRE
03:57PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nabriva Therapeutics plc of Class Action Lawsuit and Upcoming Deadline NBRV GlobeNewswire
12:02PM  Zhang Investor Law Reminds Investors of July 8 Deadline in Securities Class Action Lawsuit Nabriva Therapeutics plc NBRV GlobeNewswire
10:17AM  KSHB, NBRV & EQBK- Class Action Upcoming Deadline - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
06:11AM  Nabriva Gets EMA Acceptance for Pneumonia Drug Lefamulin Zacks
Jun-25-19 08:33PM  Hedge Funds Have Never Been More Bullish On Nabriva Therapeutics plc (NBRV) Insider Monkey
03:10PM  SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nabriva Therapeutics plc and Encourages Investors with Losses in Excess of $50,000 to Contact the Firm ACCESSWIRE
01:03PM  Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nabriva Therapeutics plc GlobeNewswire
Jun-24-19 05:00PM  FDA Type A Meetings: What You Need To Know Benzinga
04:55PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nabriva Therapeutics plc of Class Action Lawsuit and Upcoming Deadline - NBRV ACCESSWIRE
04:01PM  Nabriva Therapeutics Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application for Lefamulin GlobeNewswire
11:46AM  UPCOMING DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nabriva Therapeutics plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
10:16AM  KSHB, NBRV & EQBK- Class Action Reminder - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Jun-22-19 02:00PM  TOP RANKED ROSEN LAW FIRM Reminds Nabriva Therapeutics plc Investors of Important July 8th Deadline in the Securities Class Action NBRV GlobeNewswire
Jun-21-19 09:30PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Nabriva Therapeutics, Equity Bancshares, Revlon, and AAC Holdings and Encourages Investors to Contact the Firm GlobeNewswire
03:02PM  NBRV DEADLINE: Pawar Law Group Reminds Investors of Deadline in Securities Class Action Lawsuit Against Nabriva Therapeutics plc NBRV GlobeNewswire
03:00PM  KSHB, NBRV & EQBK-  Class Action - Bronstein, Gewirtz & Grossman, LLC GlobeNewswire
01:48PM  Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nabriva Therapeutics plc GlobeNewswire
10:38AM  KSHB, NBRV & EQBK - Class Action Reminder - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
09:35AM  IMPORTANT DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nabriva Therapeutics plc and Encourages Investors with Losses in Excess of $50,000 to Contact the Firm ACCESSWIRE
07:00AM  Nabriva Therapeutics to Present Data at ASM Microbe Demonstrating Potential of Lefamulin for Patients with Community-acquired Bacterial Pneumonia (CABP) and CONTEPO (fosfomycin) for injection to Treat Complicated Urinary Tract Infections (cUTIs) GlobeNewswire
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. Its lead product candidate is lefamulin, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection. The company is also developing CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections. In addition, it is developing lefamulin for use in the treatment of ventilator-associated bacterial pneumonia or hospital-acquired bacterial pneumonia and sexually transmitted infections, as well as Pediatric oral formulation. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Broom Colin MDDirectorAug 30Buy2.0310,17720,668208,750Sep 03 04:04 PM
Schroeder Theodore RChief Executive OfficerAug 27Buy1.7950,00089,500117,489Aug 28 04:01 PM
Lavino Francesco MariaChief Commercial OfficerAug 22Buy2.044,8009,78015,972Aug 26 09:49 PM